TVTX · Travere Therapeutics Inc
United States · RS rating 52 · As of 2026-11-03
| Price | 49.41 USD |
|---|---|
| 1-day change | +0.3% |
| RS rating (overall / 1M / 3M / 12M) | 52 / 28 / 30 / 81 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 37 / 28 / 34 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -89.3% |
| Sales growth Q/Q | -21.3% |
| Distance from 52-week high | +26.8% |
| Market cap (USD) | $3.8B |